Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence
Abstract Alpha-1 antitrypsin deficiency (AATD) is a common hereditary disorder caused by mutations in the SERPINA1 gene, which encodes alpha-1 antitrypsin (AAT; also known as alpha 1-proteinase inhibitor, A1-PI). An important function of A1-PI in the lung is to inhibit neutrophil elastase, one of va...
Main Authors: | Franck F. Rahaghi, Marc Miravitlles |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-05-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12931-017-0574-1 |
Similar Items
-
Expert Perspectives on the Management of Alpha 1-Antitrypsin Deficiency
by: Bebiana Conde, et al.
Published: (2022-07-01) -
Assessing the efficacy of Alpha1-Proteinase inhibitor (human) augmentation therapy for Alpha1-Antitrypsin deficiency – Related emphysema: Challenges and opportunities
by: L. Ross Pierce
Published: (2024-06-01) -
The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: initial report of EARCO
by: Robert A. Stockley, et al.
Published: (2023-08-01) -
Case report of a novel alpha1-antitrypsin null variant in Türkiye: Q0RİZE
by: Dilek Karadoğan, et al.
Published: (2024-02-01) -
Alpha-1-Antitrypsin Deficiency in Children: Case Series
by: Svetlana I. Melnik, et al.
Published: (2016-12-01)